Congress Questions Mental Health Spending Surge as Outcomes Worsen

The House Subcommittee on Health Care and Financial Services convened an unusual roundtable discussion March 26 that laid bare a troubling disconnect: as mental health treatment has expanded dramatically over two decades—reaching nearly 60 million American adults in 2024 compared to 27 million in 2002—outcomes have deteriorated rather than improved. Depression rates stand at historic highs. Suicide rates have climbed back to levels not seen in decades. And despite spending that ballooned 241 percent from $40.9 billion to $139.6 billion between 2000 and 2021, Americans report worse mental health today than previous generations did with far less intervention.

Chairman Glenn Grothman, a Wisconsin Republican, opened the session by acknowledging the paradox plainly. "If we are treating more people than ever before, why are we not seeing better results?" His question framed what became an afternoon of pointed inquiry into whether the mental health system, despite good intentions and enormous investment, functions effectively or simply consumes resources without delivering measurable improvement to the people it purports to help.

The data Grothman presented came largely from a Health Affairs study published in March that tracked mental health and substance use disorder spending across the 21-year period. Researchers at RTI International found that while overall medical services spending grew at an average annual rate of 2.21 percent after adjusting for inflation, mental health and substance use disorder spending outpaced that significantly at 3.27 percent annually. By 2021, these conditions accounted for 5.5 percent of all medical services spending, up from 4.5 percent in 2000.

The spending surge resulted primarily from treating more patients rather than higher costs per patient, according to the study authors. More people sought help, more providers offered services, and insurance coverage expanded—developments generally understood as positive within public health frameworks that emphasize reducing treatment barriers and increasing access. But the roundtable's premise challenged that assumption: if access improvements correlate with worsening population-level outcomes, does expanded treatment capacity represent progress or something more complicated?

The youth data proves particularly stark. Between 2016 and 2022, antidepressant prescriptions for individuals aged 12 to 25 increased by 63 percent, with more than 221 million prescriptions dispensed to 18 million young people during that six-year window. Yet mental health outcomes for adolescents and young adults declined sharply during the same period. In 2021, 57 percent of teenage girls reported persistent feelings of sadness or hopelessness, compared to 36 percent just a decade earlier—a 21-percentage-point increase over a relatively brief span.

Grothman emphasized the economic dimensions beyond direct treatment costs. More than one in three Social Security Disability Insurance beneficiaries now receive benefits due to mental disorders, making mental health conditions one of the largest drivers of a program originally designed for people with severe physical limitations preventing employment. The chairman noted this represents a substantial shift in how disability benefits function, raising questions about whether mental health conditions receive appropriate support through employment assistance and treatment rather than long-term income replacement designed for fundamentally different circumstances.

Individual financial burdens have grown alongside public expenditures. Grothman cited data indicating one in ten Americans have gone into debt to pay for mental health care—a proportion that raises questions about affordability despite expanded insurance coverage. Whether debt stems from high deductibles, narrow provider networks requiring out-of-network payments, insufficient insurance coverage for intensive treatment, or services not covered at all remains unclear, but the financial strain adds another dimension to the access versus outcomes discussion.

The roundtable featured three invited experts: Dr. David Hyman, an adjunct scholar at the Cato Institute and professor of health law and policy at Georgetown Law; Dr. Sally Satel, a senior fellow at the American Enterprise Institute, practicing psychiatrist, and lecturer at Yale School of Medicine; and Laura Delano, founder of the Inner Compass Initiative and a prominent voice in movements critiquing over-medicalization of psychological distress. The diversity of perspectives—spanning libertarian health policy analysis, clinical psychiatric practice, and lived experience skepticism of mainstream mental health treatment—suggested Grothman sought perspectives beyond conventional mental health advocacy organizations that typically dominate congressional hearings on these issues.

Grothman explicitly clarified what the roundtable was not intended to address: "This is not an argument against mental health care, nor is it an attempt to stigmatize those seeking help." His framing positioned the discussion as examining system effectiveness rather than questioning whether people experience genuine psychological suffering or benefit from intervention. But the underlying tension remains difficult to navigate—how to critique treatment outcomes, prescribing practices, and spending effectiveness without inadvertently discouraging people from seeking help when they need it or reinforcing stigma that already deters many from accessing care.

The chairman referenced the Trump Administration's MAHA (Make America Healthy Again) Commission's focus on "over-medicalization" and its directive to evaluate pediatric prescribing patterns as evidence that questions about current mental health treatment approaches are being taken seriously at the executive branch level. Whether that evaluation leads to meaningful policy changes, restricts access to medications some patients find helpful, or primarily serves political messaging remains contested among mental health professionals, patient advocates, and policy analysts observing these developments.

One interpretation of the data holds that expanded access inevitably captures people with milder conditions who previously went untreated, diluting apparent effectiveness while still providing real benefit to those individuals—even if population-level metrics don't reflect improvement. From this view, more people receiving treatment represents progress even when aggregate outcomes appear stagnant or worse, particularly if underlying stressors driving mental health struggles (economic precarity, social isolation, community breakdown) have intensified during the same period independent of treatment system changes.

An alternative interpretation suggests current treatment modalities, despite good intentions, prove less effective than assumed—or effective for some patients while harmful for others in ways that aggregate data obscures. This perspective questions whether medical model approaches to psychological distress, particularly medication-focused interventions for conditions without clear biological markers, deliver meaningful long-term benefit or primarily provide short-term symptom management while obscuring underlying issues requiring different interventions entirely. Proponents of this view often emphasize social determinants of mental health, arguing that treating individuals while ignoring economic inequality, housing instability, workplace exploitation, and community fragmentation addresses symptoms without touching root causes.

A third possibility, less discussed but implicit in the roundtable's framing, holds that mental health systems have expanded without adequate attention to quality, training, evidence-based practice, or appropriate matching of interventions to patient needs—creating a situation where more people receive care, but much of that care proves substandard or misdirected. From this angle, the problem isn't treatment itself but poor implementation: therapists using ineffective approaches, prescribers medicating too quickly without adequate evaluation, insufficient integration between mental health and other healthcare, fragmented care that loses patients between episodes, and outcome tracking too weak to distinguish effective from ineffective providers.

The roundtable format Grothman chose—informal discussion rather than structured testimony—aimed to facilitate deeper exploration of these competing interpretations rather than positioning witnesses to deliver prepared statements emphasizing their organizations' preferred policies. Whether that format generated substantive policy recommendations beyond general agreement that current approaches aren't working remains unclear, as the House Oversight Committee did not immediately release detailed transcripts or witness testimony beyond Grothman's opening remarks.

The political context matters. The MAHA Commission Grothman referenced reflects Robert F. Kennedy Jr.'s prominent role in the Trump Administration's health policy agenda, bringing with it skepticism toward pharmaceutical industry influence on medical practice and public health recommendations. Kennedy's history of vaccine skepticism and promotion of alternative health approaches shapes how mental health and addiction policy analysts interpret the administration's interest in "over-medicalization" questions—some viewing it as legitimate inquiry into prescribing practices that deserve scrutiny, others seeing it as ideologically motivated attack on evidence-based psychiatric care that could restrict access to effective treatments.

The substance use disorder spending included in the Health Affairs study adds another layer of complexity. The $139.6 billion figure encompasses both mental health and addiction treatment, two overlapping but distinct domains with different evidence bases, treatment approaches, and outcome measurement challenges. Opioid use disorder, for example, has robust evidence supporting medication-assisted treatment with buprenorphine and methadone dramatically reducing overdose mortality—a clear, measurable outcome. Depression and anxiety treatments, by contrast, rely heavily on self-reported symptom scales that may not capture full picture of functioning, recovery, or quality of life, making outcome assessment more subjective and contested.

The roundtable arrives as Congress confronts potential Medicaid restructuring through the One Big Beautiful Bill Act, which would introduce work requirements and potentially reduce federal spending significantly. Mental health and substance use treatment providers rely heavily on Medicaid reimbursement, particularly for serving low-income populations most vulnerable to losing coverage under restructured eligibility. Whether concerns about spending effectiveness raised in the roundtable translate into budget cuts, regulatory changes restricting certain treatments, or alternatively investments in different intervention approaches remains uncertain as the legislation develops.

For mental health professionals observing the roundtable, the discussion likely provoked mixed reactions. Many clinicians acknowledge current mental health systems have serious limitations—inadequate training in evidence-based therapies, over-reliance on medication for conditions where therapy proves more effective long-term, insufficient attention to trauma and social determinants, fragmented care that fails patients navigating multiple providers and systems. But they also worry that political scrutiny focused primarily on spending and population-level outcome metrics may miss the individual-level benefits patients experience even when aggregate data looks discouraging, and that criticism could be weaponized to justify cutting funding or restricting access rather than improving quality.

The antidepressant prescription data for young people deserves particular attention beyond the raw numbers. The 63 percent increase and 221 million prescriptions dispensed to 18 million individuals aged 12 to 25 between 2016 and 2022 works out to roughly 12 prescriptions per person over six years—or two per year on average. That suggests many young people receive ongoing medication management rather than brief trials, which could indicate either appropriate long-term treatment of chronic conditions or, alternatively, young patients remaining on medications indefinitely without adequate evaluation of continued necessity or alternative approaches. Distinguishing between those possibilities requires more granular data than the roundtable presented.

The teen girl mental health crisis Grothman highlighted—57 percent reporting persistent sadness or hopelessness in 2021—has generated substantial research attention trying to understand contributing factors. Social media use, academic pressure, sleep deprivation, reduced physical activity, economic anxiety about future prospects, climate change concerns, and social isolation during COVID-19 pandemic lockdowns all appear as potential contributors in various studies. Whether those underlying stressors mean treatment should expand further to address unprecedented need, or whether treatment focus diverts attention from addressing root causes, divides researchers and clinicians working in youth mental health.

The Social Security Disability Insurance data point raises questions about whether mental health conditions receive appropriate accommodation and support in workplaces versus default to disability benefits when employment challenges emerge. Some mental health advocates argue current workplace cultures remain hostile to people with mental health conditions, forcing individuals who could work with reasonable accommodations onto disability rolls instead. Others contend the disability determination process lacks rigor for subjective mental health conditions compared to physical disabilities with objective medical evidence, creating incentive structures that channel people toward long-term income support rather than treatment and vocational rehabilitation.

The roundtable's implications for addiction treatment funding warrant attention alongside mental health spending. While the hearing focused primarily on mental health outcomes, the Health Affairs study combined both categories, and substance use disorder treatment faces different challenges. The opioid crisis continues despite expanded access to medication-assisted treatment, though evidence suggests expansion remains inadequate rather than ineffective—most people with opioid use disorder still cannot access buprenorphine or methadone even in 2026. Conflating mental health spending questions with substance use disorder treatment risks undermining investment in interventions with strong evidence of reducing overdose mortality.

Grothman closed his opening remarks emphasizing that constituents "already know something is wrong. They are living it. They are watching their children struggle, taking on debt for care, and searching for answers when the system falls short." That frustration—separate from whether data supports specific policy changes—will likely drive continued scrutiny of mental health spending and outcomes regardless of how researchers and clinicians interpret the evidence. Whether that scrutiny produces system improvements or primarily cuts funding and restricts access depends on what comes next: detailed policy proposals, additional hearings examining specific interventions, or budget reconciliation provisions treating mental health spending as wasteful expenditure to reduce.

For people experiencing mental health crises or supporting loved ones through psychological struggles, the roundtable's implications remain abstract until translated into concrete policy changes. The disconnect between expanded access and worsening outcomes could lead to better treatments, more effective allocation of resources, and systems that deliver meaningful help rather than empty interventions—or it could justify cutting programs, restricting medications, and leaving more people without support during mental health emergencies. The difference matters immensely, and the roundtable itself provided more questions than answers about which direction Congress will choose.